A5052909853- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- Systemic Lupus Erythematosus Research
- Alcohol Consumption and Health Effects
- Liver Disease and Transplantation
- Opioid Use Disorder Treatment
- Chronic Lymphocytic Leukemia Research
- Long-Term Effects of COVID-19
- HIV-related health complications and treatments
- Hepatitis Viruses Studies and Epidemiology
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Hepatocellular Carcinoma Treatment and Prognosis
- Homelessness and Social Issues
- Pneumocystis jirovecii pneumonia detection and treatment
- Telomeres, Telomerase, and Senescence
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Drug-Induced Hepatotoxicity and Protection
St Vincent's Hospital Sydney
2016-2025
UNSW Sydney
2016-2025
St Vincent's Clinic
2024-2025
St Vincent's Hospital
2009-2023
The Australian Prevention Partnership Centre
2023
Australian Centre for HIV and Hepatitis Virology Research
2003-2023
Institut Pasteur
2009-2023
Center for Disease Analysis
2022
Würth (Germany)
2021
National Institute of Diabetes and Digestive and Kidney Diseases
2021
To gain a clearer understanding of the rate progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, systematic review published epidemiologic studies that incorporated assessment for has been undertaken. Inclusion criteria were more than 20 cases HCV information on either age subjects or duration infection. Of 145 examined, 57 fulfilled inclusion criteria. Least-squares linear regression was employed estimate rates cirrhosis, examine factors associated...
Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous uptake low, but new highly effective tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA on PWID three settings. A dynamic transmission model was...
Objectives: To determine the protective efficacy of highly active antiretroviral therapy (HAART) against AIDS dementia complex (ADC) relative to other initial AIDS-defining illnesses (ADIs), Australian notification data over recent years were examined. Methods: All ADIs in Australia period 1992-1997 included. Three ADI groups established: ADC; predominantly central nervous system (CNS) (toxoplasmosis and cryptococcosis); non-CNS ADIs. For each grouping, proportion total ADIs, median CD4 cell...
Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity a high barrier to resistance. We evaluated the efficacy safety of 8-week 12-week courses treatment 300 mg glecaprevir plus 120 in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection.We conducted two phase 3, randomized, open-label, multicenter trials. Patients infection were randomly assigned 1:1 ratio receive once-daily glecaprevir-pibrentasvir for either 8 12 weeks....
The aim of this study was to systematically evaluate state Medicaid policies for the treatment hepatitis C virus (HCV) infection with sofosbuvir in United States. reimbursement criteria were evaluated all 50 states and District Columbia. authors searched Web sites between 23 June 7 December 2014 extracted data duplicate. Any differences resolved by consensus. Data on whether covered coverage based following categories: liver disease stage, HIV co-infection, prescriber type, drug or alcohol...
Although 20%-40% of persons with acute hepatitis C virus (HCV) infection demonstrate spontaneous clearance, the time course and factors associated clearance remain poorly understood. We investigated to predictors among participants HCV using Cox proportional hazards analyses. Data for this analysis were drawn from an international collaboration nine prospective cohorts evaluating outcomes after infection. Among 632 HCV, 35% female, 82% Caucasian, 49% had interleukin-28 (IL28)B CC genotype...
Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID).To evaluate elbasvir-grazoprevir treating HCV PWID.Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688).Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, United Kingdom, and States.301 treatment-naive patients with chronic genotype 1, 4, or 6 were at least 80% adherent to visits for opioid agonist therapy (OAT).The immediate-treatment...
The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a ribavirin (RBV) in treatment-naïve patients HCV genotype 1 infection. Patients were randomized to one five treatments: SMV (75 or 150 mg QD) for 12 24 weeks placebo, plus Peg-IFN RBV. arms stopped all treatment at week if response-guided therapy (RGT) criteria met; not meeting RGT...
Patients with hepatitis C virus (HCV) genotype 3 infection, especially those advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotide 5B for 12 weeks previously showed high efficacy (96%) noncirrhotic infection. phase III ALLY-3+ study (N = 50) evaluated DCV-SOF ribavirin (RBV) treatment-naïve (n 13) or treatment-experienced 37)...